By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Horizon Therapeutics is one fiscally aware company that has put its money to work. Its original model was specialty pharma, which meant acquiring commercial drugs and remarketing them, usually in improved form. Now it is part of a trend of specialty pharma and other commercial companies entering the heart of the biopharma sector.
Revenues from its marketed products are fueling an integrated company with R&D focusing more on bio-based medicines such as monoclonal antibodies and genetically engineered proteins. Tim Walbert, its founding chairman, president, and CEO, has witnessed and directed the company’s transformation.